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Background: Evidence is emerging regarding the relationship 
between a dysbiosis of the human gut microbiota and a number 
of gastrointestinal diseases as well as diseases beyond the gut.  
Probiotics have been investigated in many gastrointestinal 
disease states, with variable and modest outcomes. Faecal 
transplantation is an alternative approach to manipulate the gut 
microbiota. Aims: To review the use of faecal transplantation 
therapy for the management of gastrointestinal disorders. 
Methods: Available articles on faecal transplantation in the 
management of gastrointestinal disorders, were identified 
through a Pubmed search and bibliographies of review articles 
on the subject were collated. Results: 239 patients who had 
undergone faecal transplantation were reported.  Seventeen of 
twenty two studies of faecal transplantation were in fulminant 
or refractory Clostridium difficile. Studies of faecal 
transplantation are heterogeneous regarding the patients, 
donors, screening, methods of administration, and definition of 
response. Faecal transplantation for Clostridium difficile has 
been demonstrated to be effective in 145/166 (87%) patients. 
Small numbers of patients are reported to have undergone 
successful faecal transplantation for irritable bowel syndrome 
and inflammatory bowel disease. Conclusions: Faecal 
transplantation has been reported with good outcomes for 
































































fulminant and refractory Clostridium difficile. No adverse 
effects of faecal transplantation have been reported. However, 
there are no level 1 data of faecal transplantation and reports to 
date may suffer from reporting bias of positive outcomes and 
under-reporting of adverse effects. This therapy holds great 
promise where a dysbiosis of the gut microbiota is responsible 




The possibility of modifying the gut microbiota to replace 
harmful bacteria with more favourable microbes has been 
widely explored since Metchnikoff’s observations in 1907 of 
the potential health benefits of the “Bulgarian bacillus” (1). 
With the application of molecular techniques to the study of gut 
microbiology, mounting evidence is emerging regarding the 
relationship between a dysbiosis of the human gut microbiota 
and a number of gastrointestinal diseases as well as diseases 
beyond the gut including diabetes and metabolic syndrome 
(2,3,4,5).  
In vitro studies have demonstrated a positive effect of probiotic 
bacteria on gut inflammation by modulating gut immune cells 
(6,7). Probiotics have been extensively investigated in many 
































































gastrointestinal disease states where an abnormal microbiota is 
considered pathogenic (8,9,10). The outcomes of these studies 
have however been variable and modest (10). One confounding 
factor of the probiotic approach is the comparatively low 
number and diversity of bacterial species available in a typical 
commercial probiotic preparation in comparison with the gut 
microbiota. Furthermore, probiotic bacterial strains may not be 
able to compete effectively against the complex interactions of 
an established and adapted indigenous gut microbial 
community.  
An alternative approach is transplantation of the gut 
microbiota. This is a concept that has been described in 
ruminants for some time (11). Its use as therapy in humans was 
first reported by Eiseman et al. in 1958 in the treatment of 
fulminant pseudomembranous enterocolitis (12). Over the 
subsequent decades, there have been a small number of case 
reports and case series of faecal transplantation for Clostridium 
difficile (13-29) and also constipation (16,30,31), irritable bowel 
syndrome (16,30) and inflammatory bowel diseases (16,30,32,33).  
In recent years there has been a resurgence of interest in this 
procedure and its potential to modify the gut microbiota.   
Reports of the procedure have originated from Canada and the 
United States, Australia and Northern Europe, but the methods 
of faecal transplantation, screening of donors and patient 
































































groups treated with this therapy have varied greatly. In this 
article, we review the use of faecal therapy since the 1958 
report of Eiseman et al. Available articles on the use of faecal 
transplantation in the management of human gastrointestinal 
disorders, which were identified through a Pubmed search 
(15.1.11)  and bibliographies of review articles on the subject 
were collated. Articles including patients that were previously 
described or articles that were not available in English were not 
reviewed. The included publications encompassed different 
gastrointestinal pathologies, varying methods of treatment, 
screening and duration of follow up. Twenty two reports of 
faecal transplantation meeting the inclusion criteria, were 
identified. Ten of these were published since 2005, 
demonstrating the recently renewed interest in this area. In 
total, there are 239 patients who have undergone faecal 
transplantation reported. 
Patient Details 
The majority of patients undergoing faecal transplantation were 
treated for Clostridium difficile after standard treatments had 
failed. Borody et al. in 1989 (16) reported 55 patients treated for 
constipation, diarrhoea, abdominal pain, ulcerative colitis or 
Crohn’s disease. This report did not specify the numbers of 
patients with each condition, although out of five cases 
described in more detail, two patients had irritable bowel 
































































syndrome, one ulcerative colitis, one Crohn’s disease and one 
Clostridium difficile diarrhoea. Andrews et al. (31) described 
faecal enema treatment for two patients with constipation and 
in the recent paper from Grehan et al. (32), nine patients had a 
diagnosis of constipation or diarrhoea predominant IBS and one 
patient had Crohn’s disease. One patient in the series from Aas 
et al. (20) had Clostridium difficile diarrhoea on a background 
of Crohn’s colitis. Seven other patients with ulcerative colitis 
are reported to have undergone faecal transplantation (32,33).  
Faecal transplantation has been described in patients as young 
as two years old (24) to patients over 90 years of age (23). 
Several reports include patients with serious co-morbidities. 
Three of the four patients reported by Eiseman et al. (12) were 
in a critical condition requiring the use of vasopressors. In the 
patients reported by Bowden et al. (13), eight had a previously 
treated carcinoma, two chronic renal failure and two an aortic 
aneurysm. In the study by Aas et al. (20) five patients 
undergoing faecal transplantation were hospitalised and of 
those treated as outpatients, three were nursing home residents. 
MacConnachie et al. (22) described faecal transplantation in 
eighteen patients, eleven of whom were hospitalised with 
significant co-morbidity and a high proportion having 
hypoalbuminaemia, leucocytosis and renal dysfunction before 
faecal transplantation. The patient in the report of You et al. 
































































(21) was treated in an intensive care unit with vasopressors and 
continuous veno-venous haemofiltration.  
 
Donor Screening 
The potential risk of transmission of viral, bacterial or parasitic 
infection during the course of faecal transplantation is a 
concern. No guidelines currently exist regarding screening 
before faecal transplantation. A number of studies have 
proposed screening procedures (20,24). In a recent review of 
faecal tranplantation for recurrent Clostridium difficile (34) 
Bakken suggests a screening process based on previous studies. 
However, without established guidelines or data from 
randomised controlled trials, ethical approval for the procedure 
has to date depended on physician discretion with patient and 
donor consent, local hospitals’ or authorities’ approval or 
occurred within the framework of ethically approved research 
studies. 
Screening methods of stool donors are not always detailed. In 
the majority of reports a spouse or partner, close relative, or 
household member of the patient is preferred as the stool donor. 
However, in a number of reports, donors who are unrelated 
healthy individuals have been used (13,18,33). Earlier cases did 
not employ rigorous screening protocols, whereas more 
































































recently, increased screening of donors’ medical histories, 
blood and stool tests have been implemented.  
Donors have been screened for a history of gastrointestinal 
illness, cancer or polyps, hospitalisation within the three 
previous months (25) and between 6 weeks (33) to 6 months (20) 
without the use of antibiotics. Screening blood tests have 
included full blood count and liver function tests (31) as well as 
screening f viral pathogens including  HIV 1+2 (17-20,22-
27,29,32), HTLV I/II (25) hepatitis A, B and C (18-20,22-25,29,33), 
CMV, EBV (18,33) and also for Treponema pallidum (20,22-
24,32) and Helicobacter pylori antibody (25).  
Donor faecal specimens have been screened for Salmonella 
spp., Shigella spp., Campylobacter spp., Staphylococcus 
aureus,  Aeromonas hydrophila, Yersinia spp., Vibrio 
parahaemolyticus, Vibrio cholerae, Candida albicans, 
Escherichia coli O157 and Clostridium difficile toxins A and B  
(17,18,20,22-29,33). Stool microscopy has been screened for 
protozoa (trophozoites and cysts), helminths and ova including 
Entamoeba histolytica, Giardia lamblia, Microspora spp. 
(20,22-25,27,33), Cryptosporidium spp. (25), Dientamoeba 
fragilis, Blastocystis hominis, Ascaris lumbricoides, trematodes 
and tape worms (20,22-25,27,33).  
(Table 1).  
































































Route of Administration 
The initial report of Eiseman et al. described administration of 
faecal enemas (12), which has been replicated in other studies 
(13-15,17,18,21,25,30-33). Others subsequently have used 
instillation via a colonoscope to the right colon (19,26-30) or 
instillation of donor faeces via nasogastric tube (20,22-24) or 
duodenal (29) or nasojejunal intubation (13,30). The study of 
Grehan et al. employed a combination of colonoscopic 
instillation followed by enemas or nasojejunal tube (30). The 
majority of studies entailed a single administration of donor 
faeces. Some studies used repeated infusions over 2 to 15 days 
(12-15,17,31,33). In the study by Garborg et al. (29), six patients 
underwent a second infusion of donor faeces having not 




Preparation of the patient prior to faecal transplantation has 
varied depending on the method of administration of the donor 
stool.  Studies in which donor stool is instilled at colonoscopy 
or via rectal enemas include patient preparation with bowel 
lavage treatments. Bennet and Brinkmann describe a bowel 
sterilisation procedure (32) prior to transplantation of donor 
































































stool. Persky and Brandt described the use of prior bowel 
lavage with polyethylene glycol (19). The series of Borody et al. 
in six patients with refractory ulcerative colitis, gave seven to 
ten days of treatment with vancomycin, metronidazole and 
rifampicin prior to bowel lavage (33). This protocol was 
repeated in the study by Grehan et al. (32). Two recent studies 
stopped treatment with metronidazole or vancomycin 24-48 
hours prior to faecal transplantation (27,29). The study by 
Silverman et al., included prior treatment with Saccharomyces 
boulardii which was continued up to 60 days after the 
procedure (25).  Patients treated at one centre in the study by 
Rholke et al. (26) were treated with loperamide immediately 
following the procedure and again 6 hours later in order 
maximise contact time of the donor faeces with the colonic 
mucosa.  
Studies of faecal transplantation administered into the upper 
gastrointestinal tract, do not report the use of prior bowel 
lavage. The method described by Aas et al. in 2003 and 
followed by those of MacConnachie, Rubin and Russell et al., 
includes pre-treatment with more than four days of vancomycin 
and 20mg of omeprazole the evening before and the morning of 
the faecal transplantation procedure (20,22-24).  
Preparation of donor stool 
































































The interval between obtaining donor stool and its 
administration to the patient has varied between studies, from 
24 hours before, 6 hours before (20,22-24) or immediately. One 
study homogenised donor stool in pasteurised cow’s milk and 
filtered the solution which was then stored at -20°C and thawed 
in water at 37°C 30-60 minutes prior to administration as an 
enema (18). Some studies have described the homogenisation of 
the stool and filtering to remove debris. The use of between 10 
to 200g of stool, diluted in 20-500ml sterile saline, has been 
reported depending on the method of administration. Studies 
using an upper gastrointestinal protocol for faecal 
transplantation instilled between 30 and 50g of stool 
homogenised with 50-250ml sterile saline. (Table 2).  
Outcomes 
In many reports of faecal transplantation response is not clearly 
defined. Resolution of symptoms is most commonly stated. 
Some papers include absence of Clostridium difficile toxin. In 
the 1989 paper by Borody et al., the indication for faecal 
transplantation in 50 of 55 patients treated was not stated. In 
this study however, 20 patients were cured, 26 responded and 9 
patients did not respond to faecal transplantation (16). In the 
paper by Grehan et al., outcomes were not stated (30).  
Excluding these studies, faecal transplantation for Clostridium 
difficile has been demonstrated to be effective in 145/166 
































































(87%) patients. Time to response is often not stated, although 
“immediate”, “prompt” or “rapid” response is often reported. 
Where time to response is stated, this has been recorded to 
occur within 24 hours to twelve days (13,18,24,18,29,33). 
Response appears durable with follow up of patients up to 8 
years following faecal transplantation (27).  
In the initial report of Eiseman et al. three of the four patients 
were described as terminally or critically ill. All of these had 
cessation of diarrhoea and were completely asymptomatic 
between 24 hours and ten days following faecal transplantation. 
The report of Bowden et al. describes response as a reduction 
in frequency of bowel motions, absence of fever, normalisation 
of leucocyte counts and increased general well being. Tvede 
and Rask-Madsen describe normalisation of bowel function as 
well as reduction in inflammatory markers and increased 
albumin levels as response to faecal transplantation. In the 
report of You et al. the patient rapidly displayed normalisation 
of leucocytosis, stabilisation of blood pressure enabling 
cessation of vasopressors and improvement in renal function 
allowing cessation of continuous veno-venous haemofiltration 
as well as normalisation of bowel function. In the reports of 
Schwann et al., Gustaffson et al., Persky and Brandt, Aas et al., 
MacConnachie et al., Khoruts et al., Rholke et al. and Russell 
et al. cessation of diarrhoea is defined as response. Five of 
































































these studies also document a change from a positive to a 
negative Clostridium difficile stool test.   
For ulcerative colitis, of eight patients reported, all have 
responded and have remained in remission from 6 months to 13 
years (32,33). Patients with ulcerative colitis in the series of 
Borody et al. responded within one to six weeks and were 
considered in remission by four months following faecal 
transplantation (33). Five out of the six patients reported in this 
series had moderate to severe disease with moderate to severe 
endoscopic findings. All of the patients were asymptomatic 
with no endoscopic evidence of active inflammation following 
faecal transplantation. (Table 3).  
Adverse events 
No studies of faecal transplantation report any adverse events 
related to the procedure. Some studies report patient deaths due 
to the underlying disease where the patient has not responded to 
the faecal transplantation. In one study in which donor faeces 
were instilled via a nasogastric tube, the patient died of 
peritonitis. Although considered unlikely, the nasogastric tube 
insertion could not be discounted to have been contributory 
(17). One patient in the study by Silverman et al. developed 
irritable bowel symptoms following faecal transplantation (25). 
































































Analysis of effects of faecal transplantation on stool 
composition and faecal microbiota 
Four studies have attempted to analyse stool before and after 
faecal transplantation. Using culture, Tvede and Rask-Madsen 
observed an absence of Bacteroides before bacteriotherapy and 
during vancomycin therapy whilst patients were symptomatic. 
During follow up after bacteriotherapy (including faecal 
enemas in two patients), Bacteroides were regularly cultured 
(15). Gustafsson et al. studied stool short chain fatty acid 
concentrations before and after faecal transplantation in nine 
patients. All short chain fatty acids were found to be reduced in 
the patient group compared with healthy adults and following 
faecal enema therapy the relative distribution and absolute 
amounts of short chain fatty acids returned to patterns similar to 
healthy adults (18). More recently, using modern molecular 16S 
rRNA gene sequencing techniques, two studies have shown a 
significant change in the microbiota following faecal 
transplantation. Khoruts et al. demonstrated a reduction in 
Bacteroidetes and Firmicutes in a patient with Clostridium 
difficile diarrhoea. Following faecal transplantation there was a 
rapid change in the patient’s microbiota to a composition that 
was highly similar to that of the healthy donor for at least four 
weeks (the duration of follow-up stool analysis) (28). Grehan et 
al. undertook analysis on the stool of 10 patients who 
































































underwent faecal transplantation. A dramatic change was 
shown in the recipients’ microbiota to a composition similar to 
their donors’ microbiota. This study analysed stool from 
patients up to 24 weeks following faecal transplantation 
demonstrating a durable change in the recipients’ microbiota up 
to 24 weeks (30). 
Conclusions 
Evidence regarding the use of faecal transplantation as a means 
of modifying the gut microbiota and effecting cure of 
gastrointestinal illness is accumulating. To date the majority of 
studies of faecal transplantation have been in fulminant or 
refractory Clostridium difficile. However, studies of faecal 
transplantation to date are heterogeneous regarding the patients 
treated, donors used, optimal screening protocols, methods and 
frequency of administration, and definition of response. 
Furthermore, reports to date may suffer from reporting bias of 
positive outcomes and under-reporting of adverse effects.  
Faecal transplantation, a therapy used for more than half a 
century, could hold great promise as a future treatment where a 
dysbiosis of the gut microbiota is responsible for disease. This 
therapy is inexpensive as well as being effective in some cases. 
Standardised controlled studies are necessary to ascertain the 
most effective regimen as well as the most acceptable method 
of treatment. Two randomised controlled studies of faecal 
































































transplantation in Clostridium difficile are on-going in North 
America and Europe and results from these are eagerly awaited 
as well as a study of faecal transplantation in metabolic 
syndrome.  Studies of faecal transplantation for other 
gastrointestinal diseases where a dysbiosis of the gut 
microbiota is evident are necessary. Rigorous screening of 
potential donors is essential as is the use of partners or close 
relatives as donors to minimise the potential for transmitting 
disease. Close monitoring and long term follow up are 
necessary. Combining clinical studies with molecular analysis 
of the microbiota and the effects on the immune response may 
significantly enhance our understanding of the gut microbiota 
and its relationship with health and disease.  
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Review article: Faecal transplantation. Tables. 
Table 1. Suggested screening investigations 
Sample Investigation 
Blood Full Blood Count, Liver Function Tests 
 Hepatitis A,B,C 
 HIV 1+2, HTLV I/II 
 CMV, EBV 
 Treponema pallidum 
  
Stool Selective stool culture 
 Clostridium difficile toxin A and B 
 Microscopy for ova, cysts and parasites 
 
 
Table 2. Methods of faecal transplantation 
 Upper Gastrointestinal Tract Lower Gastrointestinal Tract 
Donor stool collection prior to 
transplantation 
≤ 6 hours (13,20,22,24,30) ≤ 24 hours (14,17,25-27,30,33) 
Bowel cleansing No (13,20,22,24,30) Yes (colonic instillation) (26-
28,20,32,33) 
Donor stool volume 30-50g (20,22,24,29) 10-200g (15,18,19,21, 25-30,33) 
Volume of dilution in saline 50-250ml (20,22,24,29) 20-500ml (15,17-19,21, 25-30,33) 
Volume instilled 25-200ml (20,22,24,29) 20-500ml (15,17-19,21, 25-30,33) 





































































Table 3. Summary of the outcome studies of faecal transplantation  
Author Year Indication Number of 
Patients 
Route of faecal 
instillation 




Eiseman  1958 PMC 4 Rectal 4/4 2 days  
Bowden  1981 PMC 16 Rectal/Jejunal 14/16 1-12 days 5 days- 3years 
Schwan 1984 Relapsing CDAD 1 Enema 1/1  9 months 
Tvede 1989 Relapsing CDAD 2 Enema 1/2   6 months 
Bennet 1989 UC 1 Enema 1/1  6 months 
Borody 1989 IBS, IBD, CDAD 55 Enema 26 cure 
20 response 
9 no response 
 1-12 months 
Andrews 1992 Constipation 1 Enema 1/1  18 months 
Paterson 1994 Chronic CDAD 7 Enema 7/7  2 years 
Gustaffson 1998 AAD/CDAD 9 Enema 9/9 6-10 days 18 months 
Persky 2000 Recurrent CDAD 1 Colonic 1/1  5 years 
Aas 2003 Recurrent CDAD 18 Nasogastric 15/18  90 days 
Borody 2003 UC 6 Enema 6/6 1-6 weeks 1-13 years 
You  2008 Fulminant 
CDAD 
1 Enema 1/1 36 hours  
MacConnachie 2009 Recurrent CDAD 15 Nasogastric 11/15  4-24 weeks 
Rubin 2009 CDAD 12 Nasogastric 10/12  90 days 
Khoruts 2010 Chronic CDAD 1 Colonic 1/1 2 days 6 months 
Rholke 2010 Relapsing CDAD 19 Colonic 19/19  6 months- 5 
years 
Russell 2010 Relapsing CDAD 1 Nasogastric 1/1 36 hours 6 months 
Yoon 2010 Refractory/ 
Recurrent CDAD 
12 Colonic 12/12  3 weeks- 8 
years 
Garborg 2010 Recurrent CDAD 40 Duodenal/Colonic 33/40 24 hours  
Silverman 2010 Chronic CDAD 7 Enema 7/7   
 
































































PMC- Pseudomembranous colitis; CDAD- Clostridium difficile associated diarrhoea; AAD- antibiotic associated 
diarrhoea; IBS- Irritable bowel syndrome; IBD- Inflammatory bowel disease; UC- ulcerative colitis.  
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